HHS Report on Youth Gender Care Faces Criticism from Medical Experts

The U.S. Department of Health and Human Services (HHS) on Wednesday updated its assessment of evidence and best practices regarding gender dysphoria in children and adolescents. This update follows significant backlash from respected medical organizations, including the American Psychiatric Association.

Initially released in May, the report titled “Treatment for Pediatric Gender Dysphoria: Review of Evidence and Best Practices” was commissioned under a January executive order from former President Donald Trump. This order directed HHS to compile a review focused on promoting the health of children who express gender dysphoria.

Key Findings of the HHS Review

The HHS review synthesized numerous systematic reviews regarding treatments for youth experiencing gender dysphoria. In doing so, it articulated serious concerns surrounding medical interventions such as puberty blockers, cross-sex hormones, and surgical procedures. The report highlighted risks that include potential infertility, sexual dysfunction, impaired bone density, adverse cognitive effects, cardiovascular risks, and other psychiatric consequences.

The updated document identifies nine contributors, including physicians, researchers, and ethicists. Notably, it adds a supplement that compiles nine peer reviews conducted post-publication, along with the authors’ responses. Minor corrections for clarity were also included, as well as disclosures regarding conflicts of interest.

Authors Defend the Report Against Criticism

In an interview with Fox News Digital, senior fellow at the Manhattan Institute Leor Sapir and MIT philosopher Alex Byrne, both authors of the review, emphasized that the fundamental conclusions of the May report remain largely intact. They noted that the evidence supporting pediatric medical transitions is “very weak,” while evidence indicating potential harms is “stronger.” They also pointed out that much of the existing research in the realm of youth gender medicine tends to be methodologically flawed or biased.

According to the authors, many studies in this field come from clinics promoting such interventions, leading to exaggerated claims of benefits and underreporting of associated harms. They contend that, even with stronger evidence, ethical and diagnostic challenges would still exist.

As they aptly stated, there currently exist no randomized controlled trials specifically focused on pediatric gender medicine. They expressed concern that clinicians struggle to differentiate between minors who may undergo a lifelong struggle with their gender identity from those whose distress is temporary.

Pushback from Medical Associations

The World Professional Association for Transgender Health, along with the AAP and the APA, criticized the initial May report shortly after its release. They asserted that the report misrepresents the medical consensus and lacks adequate author identification.

In response, HHS revealed that it invited these associations to partake in the peer review process. However, only the APA chose to engage. The APA’s review criticized HHS’s methodology, claiming it lacked transparency and necessary details about study selection and analysis.

Despite this criticism, the HHS insisted that its processes are fully documented in the report’s appendix and evaluated by two external experts. Their evaluations deemed the methods sound and effective.

Welcoming Dialogue in Scientific Criticism

Sapir and Byrne expressed openness to scientific scrutiny but lamented the AAP and Endocrine Society’s decision not to participate in the peer review. They remarked that engagement from these organizations could have enriched the discourse surrounding pediatric medical transition.

These authors argued that many influential medical associations promote pediatric medical transition while failing to address legitimate scientific critiques. They stressed the importance of children receiving the highest standard of care and expressed disappointment in the reluctance of prominent medical groups to engage constructively.

Political Accusations and Public Perception

Addressing claims that their review is politically motivated, the authors firmly rejected this notion. They asserted that their team represents a politically diverse coalition committed to the principles of evidence-based medicine.

In a press release, National Institutes of Health Director Jay Bhattacharya praised the report as a significant milestone for American medicine. He emphasized that the documented evidence illustrates the risks faced by vulnerable children—a concern that should guide medical research, not ideology.

Response from Medical Organizations

The AAP did not respond to requests for commentary from Fox News Digital. The Endocrine Society indicated that it refrained from participating in the HHS review due to uncertainty about the peer review process. Nevertheless, it affirmed its commitment to evidence-based healthcare for transgender youth.

The organization noted that mental health care remains a vital component of care for transgender individuals, although they cautioned that treatment decisions should be tailored to each individual case. They indicated that interventions like hormone therapy are essential in certain scenarios but should only be pursued after careful consideration.

It is essential to highlight that such medical interventions are relatively rare. Statistics indicate that fewer than one in 1,000 U.S. adolescents with commercial insurance received treatment between 2018 and 2022, according to a study by Harvard.

In summary, the discourse surrounding pediatric gender care remains heated and complex. As various stakeholders engage in discussions about evidence and best practices, the welfare of youth experiencing gender dysphoria remains paramount.

Fox News’ Melissa Rudy contributed to this report.